20229
ORBO™ 52, gel de silice activée de petite taille (20/40), 150/75 mg, pack de 50
W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Synonyme(s) :
Tube de silice activé ORBO™
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
UNSPSC Code:
47131900
NACRES:
NB.21
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
material
W,W,F separators, silica gel
agency
NIOSH 2002,2003,2004,2005,2010,2013,2014, OSHA 16,21
product line
ORBO™
composition
Bed A, 150 mg , Bed B, 75 mg
packaging
pkg of 50 ea
manufacturer/tradename
ORBO™ 52 Small
technique(s)
active air sampling: suitable
O.D. × L
6 mm × 75 mm
matrix
Activated silica gel
particle size
20-40 mesh
application(s)
air monitoring
environmental
industrial hygiene
Catégories apparentées
General description
- ORBO™ 52 Small Activated Silica Gel (20/40) 150/75 mg solvent desorption tube is designed for gas and vapor sampling.
- It contains two beds of the same selective adsorbent separated by glass wool or foam.
- Dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.
Legal Information
ORBO is a trademark of Sigma-Aldrich Co. LLC
Classe de stockage
11 - Combustible Solids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique